ArticleOncoimmunology2013

Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.

Karine Poussin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.